Navigation Links
Nanoly Bioscience to Develop CU-Boulder Vaccine Stabilization Technology
Date:9/11/2013

Boulder, CO (PRWEB) September 11, 2013

Nanoly Bioscience of Boulder and the University of Colorado recently entered into an option agreement that will enable the startup company to develop a technique for protecting vaccines during delivery to rural and less-developed areas of the world.

The most needed vaccines in developing countries are for measles, tetanus, polio, pertussis and diphtheria, all of which — like most vaccines — must be kept at between 35-45 degrees Fahrenheit (2-8 degrees Centigrade) during transportation, delivery and storage. Outside of this range, vaccines begin to degrade and become ineffective. Maintaining this “cold chain” during transportation and delivery is challenging even in developed areas, and storing vaccines at appropriate temperatures is a serious problem in remote areas where electricity is absent or unreliable.

A research team led by CU-Boulder Distinguished Professor Kristi Anseth of the chemical and biological engineering department and the BioFrontiers Institute developed a unique material that is being adapted to solve the problem, which is estimated by the World Health Organization to cause more than a quarter of the total wastage of liquid vaccines worldwide. Anseth’s group created a unique “nano-polymer” material that can be customized and blended with any vaccine to protect against thermal damage during transportation, ultimately improving vaccine availability in remote locations.

“We’re thrilled to be adapting CU technology and working toward a solution for such an important problem,” said Balaji Sridhar, a member of Anseth’s lab who co-founded Nanoly in 2012 along with Anseth lab colleague Mark Tibbitt and co-founders from several other institutions. In 2013, the company placed second in the CU Denver business plan competition. Nanoly Bioscience also won the Duke University Startup Challenge in 2012.

“We are excited that Nanoly has optioned Dr. Anseth’s polymer technology,” said MaryBeth Vellequette of the University of Colorado Technology Transfer Office, who is the director of technology transfer for CU-Boulder. “Nanoly has a very dynamic team that is passionate about developing this technology and we are eager to continue working with them as this venture grows.”

The CU Technology Transfer Office pursues, protects, packages and licenses to business the intellectual property generated from research at CU. The office provides assistance to faculty, staff and students, as well as to businesses looking to license or invest in CU technology. For more information about technology transfer at CU visit http://www.cu.edu/techtransfer.

For more information about Nanoly Bioscience visit http://www.nanoly.info. For more information about CU-Boulder visit http://www.colorado.edu. For more information on the CU System visit http://www.cu.edu.

-CU-

Read the full story at http://www.prweb.com/releases/2013/9/prweb11114040.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
4. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
5. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
6. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
7. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
8. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Roka Bioscience Secures $47.5 Million in Series D Financing
11. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):